CatalystWireBeta

UK small-cap RNS · 28 Sep 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 15:34
    Distil DIS £1.2m
    Delay in Annual Results; update ; funding progress Results
    The audit cannot be completed until funding is secured, so the 2026 accounts miss the AIM deadline and trading is suspended from 1 October. This points to material doubt over working capital.
    Balance-sheet stress / refinancing outlook mixedfirst in 6 months +9.1% on the day
    Moved: Board and leadership reshuffle: Announced; CEO appointment subject to due diligence → CEO in post; NED appointments conditional · September 2025 equity fundraise: Partly eased by Ardgowan cash payments → Latter stages; expected October; not guaranteed · Strategic review: Distributor and route-to-market arrangements under review → Review largely complete; new strategy agreed
  2. 14:51
    Director/PDMR Shareholding Director dealing
  3. 14:00
    Director/PDMR Shareholding Director dealing
  4. 11:30
    Disposal of Boom Battle Bar
    Exits Boom, whose LFL fell 8% in a sector down about 9%, for £5m cash plus up to £6m earn-outs. Net debt falls to c.£3m and focus moves to Escape Hunt, but Boom was sold below its £21.3m book value.
    Disposal of a part (break-up) £11.0m · 43% of mcapoutlook mixedfirst since Oct 2023 +1.4% on the day
    Moved: Keep average Debt:EBITDA at about 1.0x (pre-IFRS 16).: pending → changed – Leverage target is now net debt to EBITDA of no more than 1.5x from end of FY27, against about 1.0x average before. · Double pre-IFRS 16 Group Adjusted EBITDA by March 2028.: delayed → changed – With Boom sold, the group EBITDA target is reset to at least £4m by FY27 and £8m by FY31. · Reach £100m run-rate sales and £15m adjusted EBITDA by March 2028.: delayed → changed – Old £100m sales and £15m EBITDA target for March 2028 is replaced by £30m sales and £8m EBITDA by FY31.
  5. 11:22
    Tender Offer - Results Announcement Results
    (incorporated in England under the Building Societies Act 1986)
    Capital return +0.0% on the day
  6. 10:33
    Director/PDMR Shareholding Director dealing
  7. 10:05
    2026 Half Year Results Results
    H1 beat the 34-42 kboepd production guidance, free cash flow turned positive at $4m after $70m refinancing costs, and reserves rose; the August FCF upgrade is confirmed, not new.
    Legal & regulatory ahead of expectationsoutlook positive −1.4% on the day
    Moved: Jubilee drilling and seismic programme: 2025-26 campaign complete; Campaign 2 contracted → 2025-26 campaign complete; Campaign 2 contracted · TEN FPSO acquisition: SPA signed; completion expected end Q1 2027 → SPA signed; completion expected end Q1 2027 · Ghana tax disputes and receivables: Historic gas receivables recovered → Historic gas receivables recovered
  8. 09:30
    Director/PDMR Shareholding Director dealing
    Notification of a transaction by a Person Discharging Managerial Responsibilities ("PDMR")
    Insider conviction 5 director buys in 3 months – usually about 2 −0.8% on the day
  9. 07:44
    Acquisition of 11 MWp PV in Lombardy
    Adds two Stradella sites (about 11 MWp) beside Stradella 1, building a ~20 MWp Pavia cluster and lifting the pipeline to ~223 MWp. Land cost of about EUR 1.08m is payable only after STMG acceptance, limiting cash outlay now.
    Disposal of a part (break-up) outlook positive +0.0% on the day
    Moved: Italian solar development pipeline: Pipeline about 212 MWp; target now 240 MWp → Pipeline about 223 MWp; target 240 MWp · Partial sale of solar portfolio: Non-binding MoU; further sale talks ongoing → Buyer talks advancing; MoU non-binding
  10. 07:30
    Bodycote BOY £1,541m
    Publication of Scheme Document
    Scheme Document for Veritas's recommended cash offer is published and the board unanimously backs it. CVC has stepped aside, so shareholders now vote on 21 October 2026 and the deal is expected to complete in Q1 2027.
    Takeover target −3.1% on the day
    Moved: new: Offer for the company – Scheme Document published; shareholder votes pending
  11. 07:01
    Half-year Results Results
    Qualified pipeline is up six-fold since Q3 2025 to £63m, about 95% HQ and GMP, showing the new commercial team is building clinical-stage demand. It has not yet become revenue, which was only £0.3m in H1.
    Dilutive fundraise below expectationsoutlook mixedfirst since Oct 2023 +0.0% on the day
    Moved: Leadership transition and commercial push: New personalised-mRNA offering added under new CEO → Pipeline built; H1 revenue weak · opDNA clinical supply contracts: Second clinical supply deal, Phase I cell therapy → Two clinical supply deals signed
  12. 07:01
    Half-year Results Results
    Half Year results for the six months ended 30 June 2026
    Upgrade / downgrade cycle ahead of expectationsfirst in 8 months +15.2% on the day
  13. 07:01
    Half-year Results Results
    Continuing adjusted EBITDA swung to a £0.3m profit from a £0.9m loss on 4% recurring revenue growth and lower costs, confirming the cost reset, though the sale process ended without a bid.
    Sale process / strategic review outlook positivefirst in 1 year −28.9% on the day
    Moved: Formal Sale Process: Non-binding proposals received; 30p floor set → Terminated; no recommendable offer (closed) · Cost reset and return to growth: £4m cost saving complete; EBITDA profitable → Standalone two-year value-creation framework
  14. 07:00
    La India Development and La Grecia Exploration Update
    Reaffirms December 2026 first gold at La India, with the US$27m fleet loan now fully drawn and plant installation advancing; this eases the cash squeeze after cash fell to US$9.0m in July.
    Project milestones outlook positive −1.2% on the day
    Moved: La India construction: Construction advancing; equipment loan drawn → Plant installation advancing; loan fully drawn · new: La Grecia exploration – Maiden drilling; first four holes assayed
  15. 07:00
    4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program
    Extends the existing Tier 1 pharma relationship into cell therapy, with opDNA supplied for a Phase I trial. A further clinical use of the platform, but no value or volumes are stated.
    Moved: opDNA clinical supply contracts: Clinical Supply Agreement signed 20 May 2026 → Second clinical supply deal, Phase I cell therapy
  16. 07:00
    General Meeting Requisition Notice
    LBV Actio, holding 11.854%, requisitions a general meeting to remove Chair-level director Dame Dianne Thompson and appoint Stephen Brooke; the board opposes both, opening a governance fight during a recovery.
    Activist campaign first since Oct 2023 −0.3% on the day
    Moved: new: LBV requisition to replace director Thompson – Requisition received; board recommends voting against
  17. 07:00
    Completion of Sale of 2 Kalahari Copper Licences
    Completes the sale of Virgo (the Kalahari licences) to Sandfire's subsidiary, bringing in US$3m upfront cash. This funds the remaining projects and corporate costs while the Luansobe licences remain in dispute.
    Moved: Sale of Botswana Virgo licences: Conditional agreement signed; awaiting approvals → Completed (closed)
  18. 07:00
    CRL - $9.25m U.S. Govt. Funding Investment
    Funding supports pre-site development activities aimed at fast tracking full feasibility and the route to underground mining
    Project milestones outlook positive +14.3% on the day
    Moved: Redmoor drilling and MRE update: Planning granted; 22,500m programme under way → US$9.25m US funding awarded; PEP being finalised
  19. 07:00
    Sale of Klarna Stake and Compulsory Redemption
    Sells the whole remaining Klarna stake for about £34m, so the liquid holding that was funding debt repayment and working capital is converted to cash and most of it is returned to shareholders.
    Disposal of a part (break-up) £34.0m · 12% of mcapnext step +4.5% on the day
    Moved: Klarna IPO lock-up: Further Klarna sales funding working capital → Entire remaining Klarna stake sold (closed) · Shareholder consultation and structural review: Debt repaid; handover to self-management imminent → First compulsory redemption announced; realisation under way
  20. 07:00
    Special Dividend – GBP Dividend Rate
    Asiamet Resources Limited (AIM: ARS) refers to the Company's announcements dated 9 September 2026 and 22 September 2026 regarding the payment of a US$93.0 million special cash dividend (the "Special Dividend") to shareholders in Great British Pounds (GBP).
    Capital return +4.2% on the day
  21. 07:00
    Directorate Change Board change
    Long-serving CEO and Elemental co-founder steps down to a non-executive role as the strategic review runs, with no stated reason. He stays to support key relationships, which softens the loss.
    Moved: Strategic review for shareholder value: Board reviewing options → Review ongoing; CEO change announced
  22. 07:00
    Operational Performance for Period Ended 31 Aug 26
    Q2 and H1 FY2027 figures show Uis output growing on higher grade and throughput, and the NAD98m ore-sorting build is now funded and under way. Recovery slipped to 71% in Q2.
    Project milestones outlook positive −7.0% on the day
    Moved: Uis Ore Sorter project: Loans executed; project in execution → Funded; long-lead crushing equipment ordered
  23. 07:00
    2026 Interim Results Results
    H1 revenue rose 4.4% to €25.0m, but EBITDA was flat at €3.1m and net profit only €0.1m. Cashew still loss-making at EBITDA level; the New Bond tranche extended maturities.
    Balance-sheet stress / refinancing outlook positive −13.3% on the day
    Moved: Debt restructuring and strategic options: Book build for New Bond started → First tranche of New Bond completed · Cashew processing expansion: Processing up year on year; Q4 growth expected → H1 strong volumes; H2 progress expected · Palm oil low-season recovery: Low season; trough reportedly passed → H1 recovery confirmed; H2 low season
  24. 07:00
    Bodycote BOY £1,541m
    Statement of intention not to make an offer
    CVC, the rival bidder (earlier up to 915p), says it will not bid, so competition for Veritas's 940p firm offer is gone and the chance of a higher price falls, though the Veritas offer stays.
    Takeover target next step −3.1% on the day
    Moved: Possible offers for the company: Veritas firm offer; CVC considering position → Veritas firm offer stands; CVC out
  25. 07:00
    Trading Update Trading update
    Designers, developers, and international distributor of toys, games, and giftware
    Upgrade / downgrade cycle ahead of expectations +2.9% on the day
  26. 07:00
    2026 Half Year Results Results
    H1 production of 43.7 kboepd beat the 34-42 kboepd guidance, free cash flow turned positive at $4m after refinancing costs, and reserves rose to 121.7 mmboe. Upgraded FCF guidance from August is confirmed.
    Legal & regulatory ahead of expectationsoutlook positive −1.4% on the day
    Moved: Generate about $800m free cash flow over 2023-2025 at $80/bbl: pending → on_track – H1 free cash flow was only $4m, but full-year guidance has been raised to $170-250m at $70-100/bbl. Cumulative delivery against the 2023-25 goal is not addressed. · Complete Jubilee drilling programme about six months early: pending → delivered – The 2025-26 Jubilee drilling campaign is complete, with six producers and one water injector onstream. · Jubilee drilling and seismic programme: Five of six wells onstream → 2025-26 campaign complete; Campaign 2 contracted
  27. 07:00
    Azteca Hot Commissioning Underway & CEO interview Board change
    Hot commissioning has begun after refurbishment finished, on the end-August target or close to it. This is test running at 25%-50% of capacity, not commercial output, and nothing can be sold until the Operating Licence is granted.
    Project milestones outlook positivefirst in 9 months +0.0% on the day
    Moved: Azteca Plant restart: Refurbishment 87%, on plan; commissioning next → Hot commissioning underway; Operating Licence pending · Placing and retail offer: Placing done; retail offer open → Proceeds use now stated
  28. 07:00
    Capital Access Window: Acquisition and Fundraise Fundraise
    (“Built Cybernetics”, the “Company”, or, together with its subsidiaries, the “Group")
    Dilutive fundraise first in 8 months +0.0% on the day
  29. 07:00
    Statement regarding final offer for Capricorn Offer
    DNO says its US$5.214 cash offer is final and will not rise, so it will not top Genel's increased 434p offer. The bidding contest looks settled in Genel's favour.
    Takeover target −5.1% on the day
    Moved: DNO offer for the company: Genel increased offer recommended; DNO recommendation withdrawn → DNO says its offer is final; Genel leads
  30. 07:00
    Half-year Results Results
    Interim results show H1 revenue up to US$10.8m and gross profit doubling to US$6.6m, with non-operated output above forecast funding Paradox; first gas still undated and awaiting Enbridge approval.
    Project milestones outlook positive +0.0% on the day
    Moved: Paradox project first gas: Pre-first-gas work scaled up while approval pending → Awaiting Enbridge approval; engineering and well work funded · Paradox marketing / farm-in partner: Farm-out and US$15m CPA progressing → Negotiations continuing; marketing partner selection in latter stages
  31. 07:00
    Half-year Results Results
    The H1 net loss is £3.85m with £5.1m cash left. The 80% CBR is restated, but the efficacy readout has moved from H2 2026 into 2027 after the switch to a new formulation.
    Dilutive fundraise outlook mixed, lowered +0.0% on the day
    Moved: AO-252 Phase I trial progress: Dose escalation finishing; expansion cohorts accelerating → Reformulation under way; efficacy data pushed to 2027
  32. 07:00
    Final Results Results
    Year to March 2026 results cover the legacy property business sold since the year end; the announcement gives no figures, so they say little about the restructured shell.
    Cash shell / net cash above market value first in 9 months +0.0% on the day
    Moved: Reverse takeover shell restructuring: Approved; completion 6-8 May, then RTO search → Restructured and renamed; searching for opportunities
  33. 07:00
    Equity Fundraise of £700,000 gross Fundraise
    The Fundraise Shares will represent approximately 31.62 per cent. of the Company’s enlarged issued share capital.
    Dilutive fundraise −33.3% on the day
  34. 07:00
    SPA executed for Kamiesberg Mineral Sands Project
    Turns the preliminary RTO search into a signed US$33m deal for a large permitted mineral sands resource. Funding is not secured, the target is pre-revenue and loss-making, and completion needs shareholder approval.
    Large acquisition / reverse takeover outlook positivefirst since Oct 2023 +3.8% on the day
    Moved: Reverse takeover in mining: Preliminary; initial due diligence on several targets → SPA signed; prospectus, funding and approvals pending
  35. 07:00
    Half-year Results Results
    Interim Results for the six months to 30 June 2026
    Upgrade / downgrade cycle ahead of expectationsfirst in 1 year +0.7% on the day
  36. 07:00
    Termination of FSP
    Checkit plc, the intelligent operations platform for frontline-led organisations, today announces the termination of the Formal Sale Process (“FSP”) launched on 26 March 2026.
    Takeover target −28.9% on the day
  37. 07:00
    Final Results Results
    FY26 matched market expectations, but revenue fell 2.3% and adjusted EBITDA fell 7.4% to £17.4m. Management guides to stable FY27 revenue and a margin recovery from cost savings.
    Capital return £124.9m · 145% of mcapin lineoutlook positivefirst in 9 months −2.6% on the day
    Moved: Return of capital and debt reduction: Sale proceeds fully received; buyback running to 30 Sept → Sale settled; buyback ending; dividend to be reinstated
  38. 07:00
    Half-year Results Results
    Interims confirm the move to pilot execution: the pilot and first Teck-Hughes programme are funded without the second £2.5m Yorkville tranche. But the site is not final and the royalty is still conditional.
    Project milestones outlook positivefirst in 12 months +0.0% on the day
    Moved: Teck-Hughes tailings project development: Pilot preparation: equipment pre-ordering, site arrangements advancing → Long-lead equipment ordered; site talks advanced
  39. 07:00
    Half-year Results Results
    H1 swings to a £131,941 profit from a £180,101 loss, helped by a £628,789 unrealised fair-value gain; NAV edges up to £23.3m and cash rose after the CLN. Admin costs rose.
    New CEO / reset outlook positivefirst in 1 year +0.9% on the day
    Moved: Viura reserves update: 2027 development planning continues → 2027 development planning continues · Selva Malvezzi development wells and 3D: EIA admissible; preliminary 3D delivered → EIA admissible; preliminary 3D data delivered · El Romeral transformer and power outage: Tarba self-funding; installation due September → New transformer installed; Tarba self-funding
  40. 07:00
    Half-year Results Results
    Revenue is flat at £3.409m and gross margin fell to 46.4%, mostly on the expensing of development salaries. Adjusted EBITDA is down to £29k and the interim dividend is cut to 1.50p. Net cash holds at about £2.0m.
    Turnaround plan with targets outlook mixedfirst in 1 year −3.6% on the day
    Moved: Increase the dividend in line with growth in earnings per share.: on_track → missed – The interim dividend is cut to 1.50p from 1.75p while EPS is a loss, so the dividend is not rising in line with earnings. · Management restructuring and transformation: 2026 transition year; transformation broader than expected → 2026 transition year; execution phase starting
  41. 07:00
    Final Results Results
    Final Results for the year ended 31 March 2026
    Dilutive fundraise first in 1 year +0.0% on the day
  42. 07:00
    Increase in Price for the Recommended Acquisition Offer
    Main raises its all-cash price for the Tribal businesses from about £189.3m to about £231.2m (c.105p per share), a 66.7% premium to the 10 September price, and the Board still unanimously recommends it.
    Takeover target £231.2m · 107% of mcap +19.3% on the day
    Moved: Sale to Main Capital: Conditional agreement signed, board recommends, shareholder vote pending → Price raised to c.£231.2m; irrevocables 52.7%

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note